Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2025)

BridgeBio Pharma (BBIO) has disclosed Change in Receivables for 2 consecutive years, with $22.9 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 440.2% to $22.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $134.7 million through Dec 2025, up 4434.57% year-over-year, with the annual reading at $134.7 million for FY2025, 4434.57% up from the prior year.
  • Change in Receivables hit $22.9 million in Q4 2025 for BridgeBio Pharma, down from $39.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $233.7 million in Q1 2024 to a low of -$234.8 million in Q2 2024.